About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
New Treatment Paradigms to Address R/R MM Treatment Gaps
New Treatment Paradigms to Address R/R MM Treatment Gaps
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
P
Bispecifics in Multiple Myeloma
By
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
FEATURING
Patricia Mangan
By
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
FEATURING
Patricia Mangan
306 views
August 11, 2023
0 Comments
Login to view comments.
Click here to Login
New Treatment Paradigms to Address R/R MM Treatment Gaps
26:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Bispecifics in Multiple Myeloma
Feat.
P. Mangan
14:59
Jeffrey Zonder
Managing Adverse Events of Bispecific Antibodies
30:40
MyCancerHaven
Experts Discuss Updates in Myeloma From ASCO® 2023
Feat.
R. Vij,
L. Costa
06:11
Insights from 2023 EHA® Annual Meeting
EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-U…
Feat.
A. Varshavsky-Yanovsky
18:11
Fred Hutchinson Cancer Center
Linvo, Tec/Tal, & BiTEs - Oh My! Making Sense of Bispecific Anti…
Feat.
R. Banerjee
06:59
ecancer
ASCO® 2023 Insights: "Teclistamab for R/R MM - Summary of Long-…
Feat.
N. Van De Donk
05:22
PrecisCa
Teclistamab in R/R Multiple Myeloma: Results From the MajesTEC-1 Tri…
Feat.
A. Nooka
07:25
ecancer
Updated Data From the Phase 1/2 MajesTEC-1 Study: Evaluating Teclist…
Feat.
A. Nooka
05:20
Thomas Martin
Health-Related Quality of Life in R/R MM Treated With Teclistamab, a…
12:33
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Minimizing Uncertainty in Multiple Myelom…
Feat.
K. Patel
14:09
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…
Feat.
H. Hashmi
11:54
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Betting on BCMA in Multiple Myeloma"
Feat.
R. Vij
26:27
Fred Hutchinson Cancer Center
Treatment Considerations and Best Practices for the Use of Bispecifi…
Feat.
A. Cowan
20:19
Total Health
Total Health MDONS 2023: Updates in Hematology
Feat.
L. Mountjoy
33:17
Total Health
2023 Best of Hematology: Multiple Myeloma Updates
Feat.
A. Yee
23:11
Dana-Farber Cancer Institute
Bispecific Antibodies in Multiple Myeloma
Feat.
O. Nadeem
23:36
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient
Immunotherapy for Multiple Myeloma
Feat.
A. Cohen
22:15
Current Challenges in Hematology
Efficacy of BCMA-Targeted Therapies in Pretreated Patients With R/R …
Feat.
C. Cerchione
15:14
Philippe Moreau
EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and …
18:18
Thomas Martin
State of the Art & Next Questions: MM
34:48
Kenneth Anderson
MM Cured in 2030 - What Are the Next Steps?
Feat.
K. Anderson
15:08
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient
New Therapies for Relapsed Myeloma in 2023
Feat.
D. Vogl